COVID-19 Boosters Help Moderna And Pfizer Rake In Revenue

COVID-19 vaccine manufacturers are on the precipice of another financial windfall. Following the FDA’s approval of a “booster” third vaccine dose for immunocompromised individuals, Moderna and Pfizer have reappraised their annual profit estimates. Although the booster only applies to around 3% of the population in its first application, with looser parameters expected down the line, the earnings will have a significant effect on each company’s financial standing and future.

Between them, Moderna and Pfizer are projecting that they will make around $50 billion in vaccine sales for the year. If the pricing is similar for booster shots, it could account for an additional $12.5 billion each. Executives are surely excited by the prospect of collecting an extra 25% of annual revenue during an already-lucrative streak.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Of the two companies, Moderna is the one that most likely had its fingers crossed for booster authorization. Even though it is valued at 7 times estimated revenue over the next year, the company is tasked with generating $20 billion in annual sales to stay comfortably in the black. The future is not entirely murky, though, despite Moderna needing to find success beyond COVID-19 vaccine territory. Its stock has more than doubled in price during the first half of the year, and has grown 63% in the third quarter alone.